



Complete Summary

GUIDELINE TITLE

Providing a primary care medical home for children and youth with cerebral palsy.

BIBLIOGRAPHIC SOURCE(S)

Cooley WC. Providing a primary care medical home for children and youth with cerebral palsy. *Pediatrics* 2004 Oct;114(4):1106-13. [55 references] [PubMed](#)

GUIDELINE STATUS

This is the current release of the guideline.

American Academy of Pediatrics (AAP) Policies are reviewed every 3 years by the authoring body, at which time a recommendation is made that the policy be retired, revised, or reaffirmed without change. Until the Board of Directors approves a revision or reaffirmation, or retires a statement, the current policy remains in effect.

** REGULATORY ALERT **

FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

- [April 11, 2007, Zanaflex \(tizanidine hydrochloride\)](#): Changes to the product labeling for Zanaflex, a drug used to treat spasticity, to warn against its hypotensive and sedative effects when administered with fluvoxamine or ciprofloxacin (CYP1A2 inhibitors).

COMPLETE SUMMARY CONTENT

** REGULATORY ALERT **

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis

RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

QUALIFYING STATEMENTS

IMPLEMENTATION OF THE GUIDELINE

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

SCOPE

DISEASE/CONDITION(S)

Cerebral palsy

GUIDELINE CATEGORY

Counseling
Diagnosis
Management
Screening

CLINICAL SPECIALTY

Family Practice
Neurology
Nursing
Pediatrics

INTENDED USERS

Advanced Practice Nurses
Allied Health Personnel
Health Care Providers
Health Plans
Managed Care Organizations
Nurses
Physician Assistants
Physicians

GUIDELINE OBJECTIVE(S)

- To improve the overall quality of care of individuals with cerebral palsy and their families
- To review the aspects of care specific to cerebral palsy that a medical home should provide beyond the routine health maintenance, preventive care, and anticipatory guidance needed by all children
- To provide guidance on communication and comanagement with pediatric subspecialists and pediatric surgical specialists, therapists, and community developmental and educational teams
- To highlight the value of a primary care medical home from which care is initiated, coordinated, and monitored and with which families can form a reliable alliance for information, support, and advocacy from the time of diagnosis through the transition to adulthood

TARGET POPULATION

Children and youth with cerebral palsy and their families

INTERVENTIONS AND PRACTICES CONSIDERED

Diagnosis/Screening

1. Developmental screening during well-child care, including persistence of infantile reflexes, delayed appearance of postural and protective reflexes, asymmetrical movements or reflexes, variations in muscle tone, and delays in emergence of motor milestones
2. Rigorous neuromotor examination and standardized instruments measuring neuromotor development
3. Dysmorphology or genetics consultation
4. Brain imaging
5. Gross Motor Function Classification System
6. Referral to a multidisciplinary neuromotor clinic or team

Management

1. Proactive care coordination
 - Monitoring, interpreting, and orchestrating comanagement with specialists and specialty teams
 - Communicating with therapeutic, educational, family-support, and other community resources
 - Advocacy with payers and providers
 - Pediatric ophthalmologic and audiologic consultation
2. Managing spasticity
 - Integrated physical therapy, orthopedic and orthotic management
 - Medication: benzodiazepines, including diazepam, clonazepam, and clorazepate dipotassium; dantrolene; baclofen; tizanidine hydrochloride; nerve and motor blocks and botulinum toxin
 - Dorsal rhizotomy
 - Nutrition management including gastrostomy tube feeding
 - Management of constipation and urologic difficulties
 - Dental care
 - Pain assessment and management
 - Neuropsychological and psychoeducational assessments
 - Counseling regarding complementary therapies including "hippotherapy" (therapeutic horseback riding); not recommended/unproven therapies such as hyperbaric oxygen, nutritional supplements, "patterning" techniques
3. Long term care
 - Scheduling visits
 - Physical accessibility of facilities
 - Documentation and insurance coding
4. Supporting children, youth, and families
 - Early intervention
 - Respite care
 - Planning for transition to adulthood
 - Financial planning

MAJOR OUTCOMES CONSIDERED

- Efficacy of intervention strategies on the overall quality of care of affected individuals and their families, on the well-being and realization of potential in children with cerebral palsy, and on family resilience and coping
- Efficacy of management of spasticity on deformity, function, pain, and ease of caregiving

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Not stated

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review
Review of Published Meta-Analyses

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

1. Be aware of risk factors associated with cerebral palsy and incorporate neuromotor screening into routine developmental surveillance.
2. Provide prompt referral for early-intervention services for all children with alterations in motor development without waiting for diagnostic confirmation of cerebral palsy.
3. Partner with parents in the pursuit of a diagnosis and a culturally effective discussion of its implications for health, development, and family life.
4. Include screening for sensory impairments in the care plan for all newly identified children with cerebral palsy; brain imaging should be performed when appropriate.
5. Consider referral to a geneticist or pediatric neurologist in the presence of dysmorphic features, positive family history, or any atypical clinical characteristics.
6. Make your office a medical home that includes services such as care coordination, a written care plan, patient and family education, parent-to-parent referral, and advocacy.
7. After the definitive diagnosis of cerebral palsy, begin comanagement with a multidisciplinary neuromotor team and schedule regular chronic condition management visits in addition to regular preventive medical care.
8. Manage spasticity by using a "ladder" approach, starting with the least invasive interventions and adding treatments as needed.
9. Maintain vigilance for the new onset of comorbid conditions such as seizures, cognitive or learning disabilities, nutritional complications, etc.
10. Advocate with parents to school personnel about appropriate educational and therapeutic strategies including: physical, occupational, and speech therapy; nursing; and adaptive and assistive technology.
11. Be aware of and make timely referrals to community and state agencies providing support and services to which the child and family may be entitled.
12. Be a sensitive and useful resource for families in their exploration of complementary and alternative interventions for cerebral palsy.
13. Solicit feedback from families of children with cerebral palsy about the care and services provided in your office and how they could be improved.
14. Assess the quality of your medical home services for children with cerebral palsy and engage in systematic, incremental efforts to improve them.
15. Begin planning for the transition to adulthood with the child and family as early as possible, but no later than 12 years of age.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence supporting each recommendation is not specifically stated.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

- Primary care management of cerebral palsy provides an opportunity to implement the medical-home model and improve the overall quality of care of affected individuals and their families.
- Prevention of orthopedic complications, the achievement of alternative means of communication, the optimization of motor skills, and the close monitoring of nutrition and growth have positive effects on the well-being and realization of potential in most children with cerebral palsy. In addition, early responses to family-support needs may enhance resilience and coping and equip families with some of the "marathon skills" that caring for their child may require.
- Active and careful management of spasticity is important to decrease or prevent deformity, promote function, alleviate pain, and increase the ease of caregiving.

POTENTIAL HARMS

Adverse side effects of medications/treatments:

- Dantrolene - hepatotoxicity, weakness, gastrointestinal distress
- Tizanidine hydrochloride - sedation, dry mouth, hypotension
- Benzodiazepines (diazepam, clonazepam, clorazepate dipotassium) - sedation
- Baclofen - sedation
- Intrathecal baclofen - drug-related (hypotonia, weakness, nausea, vomiting, alteration in bowel and bladder function) and device-related (seroma, infection, catheter problems) complications. The most serious complication may result from overinfusion, usually related to programming errors, which may cause respiratory suppression and reversible coma.
- Gastrostomy tube feeding: excessive weight gain

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Living with Illness

IOM DOMAIN

Effectiveness
Patient-centeredness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Cooley WC. Providing a primary care medical home for children and youth with cerebral palsy. *Pediatrics* 2004 Oct;114(4):1106-13. [55 references] [PubMed](#)

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2004 Oct

GUIDELINE DEVELOPER(S)

American Academy of Pediatrics - Medical Specialty Society

SOURCE(S) OF FUNDING

American Academy of Pediatrics

GUIDELINE COMMITTEE

Committee on Children With Disabilities, 2003-2004

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Committee on Children With Disabilities, 2003-2004 Members: Adrian D. Sandler, MD (Chairperson); J. Daniel Cartwright, MD; John C. Duby, MD; Chris Plauche Johnson, MD, MEd; Lawrence C. Kaplan, MD; Eric B. Levey, MD; Nancy A. Murphy, MD; Ann Henderson Tilton, MD; W. Carl Cooley, MD (Past Committee Member); Theodore A. Kastner, MD, MS (Past Committee Member); Marian E. Kummer, MD (Past Committee Member)

Liaisons: Beverly Crider, Family Voices; Merle McPherson, MD, MPH, Maternal and Child Health Bureau; Linda Michaud, MD, American Academy of Physical Medicine and Rehabilitation; Marshalyn Yeargin-Allsopp, MD, Centers for Disease Control and Prevention

Staff: Stephanie Mucha, MPH

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

American Academy of Pediatrics (AAP) Policies are reviewed every 3 years by the authoring body, at which time a recommendation is made that the policy be retired, revised, or reaffirmed without change. Until the Board of Directors approves a revision or reaffirmation, or retires a statement, the current policy remains in effect.

GUIDELINE AVAILABILITY

Electronic copies: Available from the [American Academy of Pediatrics \(AAP\) Policy Web site](#).

Print copies: Available from American Academy of Pediatrics, 141 Northwest Point Blvd., P.O. Box 927, Elk Grove Village, IL 60009-0927.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on November 18, 2004. The information was verified by the guideline developer on January 3, 2005. This summary was updated by ECRI Institute on May 8, 2007, following the U.S. Food and Drug Administration advisory on Zanaflex (tizanidine hydrochloride).

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please contact the Permissions Editor, American Academy of Pediatrics (AAP), 141 Northwest Point Blvd, Elk Grove Village, IL 60007.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 10/6/2008



